Loading cancer entity…
Loading cancer entity…
Clinical trials
4,033 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (699)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07773909 | Venetoclax With Hypomethylating Agents in Newly Diagnosed AML Unfit for Intensive Chemotherapy | completed | Phase 4 | 24 | Bangabandhu Sheikh Mujib Medical University, Dhaka, BangladeshOTHER | 1 | Aug 21, 2026 | clinicaltrials |
| NCT07105319 | Ropeginterferon for Treatment Free Remission(ROPEG) | completed | Phase 4 | 65 | Dong-Wook KimOTHER | 1 | Aug 22, 2025 | clinicaltrials |
| NCT02926586 | Fludarabine and Cytarabine Versus High-dose Cytarabine for CBF-AML | completed | Phase 4 | 68 | Shanghai General Hospital, Shanghai Jiao Tong University School of MedicineOTHER | 1 | Oct 1, 2024 | clinicaltrials |
| NCT01735955 | Study to Allow Access to Nilotinib for Patients Who Are on Nilotinib Treatment in a Novartis-sponsored Study | completed | Phase 4 | 57 | Novartis PharmaceuticalsINDUSTRY | 16 | Feb 8, 2024 | clinicaltrials |
| NCT02546674 | Study Assessing Deep Molecular Response in Adult Patients With CML in Chronic Phase Treated With Nilotinib Firstline.(NILOdeepR) | completed | Phase 4 | 171 | Novartis PharmaceuticalsINDUSTRY | 1 | Jul 22, 2022 | clinicaltrials |
| NCT02200978 | A Study for Improving the Outcome of Childhood Acute Promyeloid Leukemia | completed | Phase 4 | 176 | South China Children's Leukemia GroupOTHER | 1 | May 10, 2022 | clinicaltrials |
| NCT00980018 | An Exploratory Trial to Assess the Improvement of Adverse Events in Chronic Myelogenous Leukemia Patients Treated With Imatinib When Switched to Nilotinib Treatment(MACS0999) | completed | Phase 4 | 52 | Novartis PharmaceuticalsINDUSTRY | 2 | Jul 1, 2021 | clinicaltrials |
| NCT03176849 | A Randomized Phase IV Control Trial of Single High Dose Oral Vitamin D3 in Pediatric Patients Undergoing HSCT | completed | Phase 4 | 49 | Phoenix Children's HospitalOTHER | 1 | Nov 17, 2020 | clinicaltrials |
| NCT01243489 | Compliance: Role Emerges for Success in Chronic Myelogenous Leukaemia (CML): Evaluation aND Optimisation(Crescendo) | completed | Phase 4 | 104 | Gesellschaft fur Medizinische Innovation - Hamatologie und Onkologie mbHOTHER | 1 | Dec 20, 2019 | clinicaltrials |
| NCT01578213 | Validation of Digital-PCR Analysis Through Programmed Imatinib Interruption in PCR Negative CML Patients(ISAV) | completed | Phase 4 | 112 | University of Milano BicoccaOTHER | 5 | Dec 3, 2019 | clinicaltrials |
| NCT01200355 | Posaconazole Versus Micafungin for Prophylaxis Against Invasive Fungal Infections During Neutropenia in Patients Undergoing Chemotherapy for Acute Myelogenous Leukemia, Acute Lymphocytic Leukemia or Myelodysplastic Syndrome | completed | Phase 4 | 113 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | May 7, 2018 | clinicaltrials |
| NCT01819792 | Respiratory Viral Infections During Acute Myeloid Leukemia (AML)Chemotherapy Related Aplasia(LAMVIRE) | completed | Phase 4 | 119 | Centre Hospitalier Universitaire, AmiensOTHER | 1 | Apr 23, 2018 | clinicaltrials |
| NCT01347996 | Maintenance Therapy With Ceplene® (Histamine) and IL-2 on Immune Response and MRD in Acute Myeloid Leukemia | completed | Phase 4 | 84 | Cytovia, Inc.OTHER | 1 | Nov 29, 2017 | clinicaltrials |
| NCT03332511 | Efficacy and Safety of Nilotinib in CML-CP(ENESTKorea) | completed | Phase 4 | 110 | Seoul National University HospitalOTHER | 0 | Nov 6, 2017 | clinicaltrials |
| NCT00686543 | Oral Posaconazole in High Risk Patients With Gastrointestinal Dysfunction (Study P05115) | completed | Phase 4 | 75 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Apr 7, 2017 | clinicaltrials |
| NCT00361140 | Busulfan Safety/Efficacy as Conditioning Prior to Hematopoietic Cell Transplantation (HCT) | completed | Phase 4 | 72 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Mar 3, 2017 | clinicaltrials |
| NCT01206088 | Tasigna in Glivec-resistant or Intolerant Patients in CML | completed | Phase 4 | 93 | Novartis PharmaceuticalsINDUSTRY | 1 | Feb 28, 2017 | clinicaltrials |
| NCT00171899 | Study Comparing Standard Dose and High-dose Imatinib Mesylate in Patients With Chronic Phase Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia (CML) | completed | Phase 4 | 80 | Novartis PharmaceuticalsINDUSTRY | 1 | Feb 23, 2017 | clinicaltrials |
| NCT00786812 | Study of Treatment With Nilotinib in Adult Patients With Imatinib - Resistant or - Intolerant Chronic Myeloid Leukemia in Blast Crisis, Accelerated Phase or Chronic Phase(MACS0439) | completed | Phase 4 | 89 | Novartis PharmaceuticalsINDUSTRY | 1 | Feb 23, 2017 | clinicaltrials |
| NCT01660906 | Phase IV, Open-label, Multicenter Study of Dasatinib in Chronic-Phase Chronic Myeloid Leukemia (CP-CML) Patients With Chronic, Low-grade Non-Hematologic Toxicity to Imatinib | completed | Phase 4 | 39 | Bristol-Myers SquibbINDUSTRY | 5 | Nov 22, 2016 | clinicaltrials |
| NCT01368523 | Study of Oral AMN107 (Nilotinib) in Adult Patients With Imatinib - Resistant or - Intolerant Chronic Myeloid Leukemia in Blast Crisis, Accelerated Phase or Chronic Phase Previously Enrolled to CAMN107A2109 Trial | completed | Phase 4 | 19 | Novartis PharmaceuticalsINDUSTRY | 1 | Nov 16, 2016 | clinicaltrials |
| NCT00845221 | Glivec in Pediatric Chronic Myeloid Leukemia (CML) | completed | Phase 4 | 44 | Poitiers University HospitalOTHER | 1 | Oct 11, 2016 | clinicaltrials |
| NCT00408278 | Treatment of Newly Diagnosed Patients With Acute Promyelocytic Leukemia (PETHEMA LPA 2005) | completed | Phase 4 | 300 | PETHEMA FoundationOTHER | 3 | Oct 28, 2014 | clinicaltrials |
| NCT00504764 | Treatment of Relapsed Promyelocytic Leukemia With Arsenic Trioxide (ATO) | completed | Phase 4 | 60 | PETHEMA FoundationOTHER | 1 | Oct 28, 2014 | clinicaltrials |
| NCT01041040 | LAM07: Study to Analyze the Efficacy of a Risk Adapted Treatment Strategy, Including Gemtuzumab Ozogamicin (GO) During Consolidation, for Patients With Acute Myeloid Leukemia (AML) | completed | Phase 4 | 200 | PETHEMA FoundationOTHER | 1 | Jul 31, 2013 | clinicaltrials |
| NCT00464217 | Treatment of the Acute Myeloblastic Leukaemia in Patients Over 65 Years | completed | Phase 4 | 100 | PETHEMA FoundationOTHER | 1 | Jan 5, 2010 | clinicaltrials |
| NCT00081926 | Gleevec Trial in Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia | completed | Phase 4 | 112 | Novartis PharmaceuticalsINDUSTRY | 1 | Nov 23, 2009 | clinicaltrials |
| NCT00390897 | Glivec® (Imatinib Mesylate, STI571) in Monotherapy Versus Glivec®-Interferon Alpha in the Treatment of Chronic-Phase Chronic Myeloid Leukaemia | completed | Phase 4 | 360 | PETHEMA FoundationOTHER | 1 | Nov 27, 2008 | clinicaltrials |
| NCT00487448 | SMD_FLAG-IDA_98: FLAG-IDA in Induction Treatment of High Risk Myelodysplastic Syndromes or Secondary Acute Myeloblastic Leukemia(FLAG-IDA) | completed | Phase 4 | 200 | PETHEMA FoundationOTHER | 1 | Nov 19, 2008 | clinicaltrials |
| NCT00488709 | Fludarabine, Cytarabine, Topotecan in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia(FLAT) | completed | Phase 4 | 47 | PETHEMA FoundationOTHER | 1 | Nov 18, 2008 | clinicaltrials |
| NCT00465933 | Treatment of Acute Promyelocytic Leukemia With All-Trans Retinoic Acid (ATRA) and Idarubicin (AIDA) | completed | Phase 4 | — | PETHEMA FoundationOTHER | 1 | Mar 31, 2008 | clinicaltrials |
Data updated 22 days agoSource updated Aug 21, 2026source: clinicaltrials